Cargando…

Calculating Variations in Biological Effectiveness for a 62 MeV Proton Beam

A biophysical model of radiation-induced cell death and chromosome aberrations [called BIophysical ANalysis of Cell death and chromosome Aberrations (BIANCA)] was further developed and applied to therapeutic protons. The model assumes a pivotal role of DNA cluster damage, which can lead to clonogeni...

Descripción completa

Detalles Bibliográficos
Autores principales: Carante, Mario Pietro, Ballarini, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822087/
https://www.ncbi.nlm.nih.gov/pubmed/27092294
http://dx.doi.org/10.3389/fonc.2016.00076
_version_ 1782425708194168832
author Carante, Mario Pietro
Ballarini, Francesca
author_facet Carante, Mario Pietro
Ballarini, Francesca
author_sort Carante, Mario Pietro
collection PubMed
description A biophysical model of radiation-induced cell death and chromosome aberrations [called BIophysical ANalysis of Cell death and chromosome Aberrations (BIANCA)] was further developed and applied to therapeutic protons. The model assumes a pivotal role of DNA cluster damage, which can lead to clonogenic cell death following three main steps: (i) a DNA “cluster lesion” (CL) produces two independent chromosome fragments; (ii) fragment mis-rejoining within a threshold distance d gives rise to chromosome aberrations; (iii) certain aberration types (dicentrics, rings, and large deletions) lead to clonogenic inactivation. The yield of CLs and the probability, f, that a chromosome fragment remains un-rejoined even if other fragment(s) are present within d, were adjustable parameters. The model, implemented as a MC code providing simulated dose–responses directly comparable with experimental data, was applied to pristine and modulated Bragg peaks of the proton beam used to treat eye melanoma at INFN-LNS in Catania, Italy. Experimental survival curves for AG01522 cells exposed to the Catania beam were reproduced, supporting the model assumptions. Furthermore, cell death and chromosome aberrations at different depths along a spread-out Bragg peak (SOBP) dose profile were predicted. Both endpoints showed an increase along the plateau, and high levels of damage were found also beyond the distal dose fall-off, due to low-energy protons. Cell death and chromosome aberrations were also predicted for V79 cells, in the same irradiation scenario as that used for AG01522 cells. In line with other studies, this work indicated that assuming a constant relative biological effectiveness (RBE) along a proton SOBP may be sub-optimal. Furthermore, it provided qualitative and quantitative evaluations of the dependence of the beam effectiveness on the considered endpoint and dose. More generally, this work represents an example of therapeutic beam characterization avoiding the use of experimental RBE values, which can be source of uncertainties.
format Online
Article
Text
id pubmed-4822087
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-48220872016-04-18 Calculating Variations in Biological Effectiveness for a 62 MeV Proton Beam Carante, Mario Pietro Ballarini, Francesca Front Oncol Oncology A biophysical model of radiation-induced cell death and chromosome aberrations [called BIophysical ANalysis of Cell death and chromosome Aberrations (BIANCA)] was further developed and applied to therapeutic protons. The model assumes a pivotal role of DNA cluster damage, which can lead to clonogenic cell death following three main steps: (i) a DNA “cluster lesion” (CL) produces two independent chromosome fragments; (ii) fragment mis-rejoining within a threshold distance d gives rise to chromosome aberrations; (iii) certain aberration types (dicentrics, rings, and large deletions) lead to clonogenic inactivation. The yield of CLs and the probability, f, that a chromosome fragment remains un-rejoined even if other fragment(s) are present within d, were adjustable parameters. The model, implemented as a MC code providing simulated dose–responses directly comparable with experimental data, was applied to pristine and modulated Bragg peaks of the proton beam used to treat eye melanoma at INFN-LNS in Catania, Italy. Experimental survival curves for AG01522 cells exposed to the Catania beam were reproduced, supporting the model assumptions. Furthermore, cell death and chromosome aberrations at different depths along a spread-out Bragg peak (SOBP) dose profile were predicted. Both endpoints showed an increase along the plateau, and high levels of damage were found also beyond the distal dose fall-off, due to low-energy protons. Cell death and chromosome aberrations were also predicted for V79 cells, in the same irradiation scenario as that used for AG01522 cells. In line with other studies, this work indicated that assuming a constant relative biological effectiveness (RBE) along a proton SOBP may be sub-optimal. Furthermore, it provided qualitative and quantitative evaluations of the dependence of the beam effectiveness on the considered endpoint and dose. More generally, this work represents an example of therapeutic beam characterization avoiding the use of experimental RBE values, which can be source of uncertainties. Frontiers Media S.A. 2016-04-06 /pmc/articles/PMC4822087/ /pubmed/27092294 http://dx.doi.org/10.3389/fonc.2016.00076 Text en Copyright © 2016 Carante and Ballarini. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Carante, Mario Pietro
Ballarini, Francesca
Calculating Variations in Biological Effectiveness for a 62 MeV Proton Beam
title Calculating Variations in Biological Effectiveness for a 62 MeV Proton Beam
title_full Calculating Variations in Biological Effectiveness for a 62 MeV Proton Beam
title_fullStr Calculating Variations in Biological Effectiveness for a 62 MeV Proton Beam
title_full_unstemmed Calculating Variations in Biological Effectiveness for a 62 MeV Proton Beam
title_short Calculating Variations in Biological Effectiveness for a 62 MeV Proton Beam
title_sort calculating variations in biological effectiveness for a 62 mev proton beam
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822087/
https://www.ncbi.nlm.nih.gov/pubmed/27092294
http://dx.doi.org/10.3389/fonc.2016.00076
work_keys_str_mv AT carantemariopietro calculatingvariationsinbiologicaleffectivenessfora62mevprotonbeam
AT ballarinifrancesca calculatingvariationsinbiologicaleffectivenessfora62mevprotonbeam